At Argutari Pharma we are continuously investing in cutting edge research and development to deal with some of the most incapacitating and prevalent cancers. Our aim is to have a significant impact on people's day-to-day lives. Throughout the arena of oncology, we accomplish this through exclusively incorporating our profound understanding in primary areas of biology with cutting-edge technological know-how, and working alongside our associates, scientists, medical specialists, industry colleagues and patients, to uncover and create medicines that can generate true life changing advancements in the treatment of cancer.
We are enthusiastic and dedicated to taking on the most difficult obstacles experienced throughout oncology. Our oncology specialists are constantly endeavoring to change the way in which cancer and cancer care, is addressed and to create and provide clinical innovations for patients.
This dedication and enthusiasm runs to the research into hematologic diseases, pushing advancement in chronic lymphocytic leukaemia, acute myeloid leukaemia, and multiple myeloma together with other blood cancers. Argutari Pharma is utilizing its knowledge of blood cancer for fresh scientific studies in some of the most difficult-to-treat solid tumors. Our experts incorporate deep biologic understanding with cutting-edge analysis and technological know-how to progress cancer care. Argutari Pharma is at present assessing compounds in over 200 active clinical studies in a variety of environments as the prospective treatment procedures for 20+ varieties of cancer.
Our studies have led to discovering ADCs which are monoclonal antibodies that bind directly to distinct indicators on a cancer cell and generate a cytotoxic agent. ADCs will enable the treatment to get delivered directly to the designated tumor target.
This oncology research will enable us create crucial therapeutic pathways and techniques to determine the most effective methods to treat people coping with cancer.